Posted inNews and Updates
Retatrutide and the GLP-1 Muscle Loss Paradox
Analyzing the clinical and regulatory implications of Retatrutide for GLP-1 muscle loss and the risks of off-label prescribing in the obesity treatment market.
Posted inNews and Updates
Renaming PCOS to PMOS: Strategic Shift in Diagnostic Coding
Experts advocate rebranding PCOS to PMOS to address metabolic dysregulation. Explore the implications for diagnostic protocols, pharma R&D, and clinical pathways.